Synpromics Appoints Andrei Lyne As CFO

Online, January 17, 2011 (Newswire.com) - Mr. Lyne previously spent eight years as an investment banker in UBS Investment Bank's Global Healthcare Group, advising healthcare and life science companies in the US, throughout Europe and around the world. Subsequently he has served as Senior Vice President of Business Development at Regulon, a privately-held biotech company.

Dr. Michael Roberts, CEO of Synpromics, commented, "Andrei is an important addition to Synpromics's senior management team. His many years of experience advising life science companies on financial and strategic transactions, as well as his business development experience in the biotech industry, will be invaluable as Synpromics establishes its operations and builds its unique brand."

Mr. Lyne commented, "I am very excited to be joining Synpromics at this early stage in the company's growth. Synpromics has developed impressive proprietary technology that has exceptional potential to address unmet needs in both life science research and the fields of patient diagnosis and treatment. I look forward to helping Synpromics realize the full potential of this technology by establishing a leading global position in the burgeoning field of synthetic biology."

Mr. Lyne received his Bachelor's degree from Oxford University and his MBA from New York University's Stern School of Business.